Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis

NCT ID: NCT03926637

Last Updated: 2023-01-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

3073 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-06-17

Study Completion Date

2022-12-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective is to evaluate the feasibility of the Multiple Sclerosis Performance Test (MSPT) in a clinical care setting when used by participants with Multiple Sclerosis (MS).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study Participants

Participants with MS, including CIS will complete the MSPT at their standard of care visits.

Multiple Sclerosis Performance Test (MSPT)

Intervention Type OTHER

Administered as specified in the treatment arm.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Multiple Sclerosis Performance Test (MSPT)

Administered as specified in the treatment arm.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use confidential health information in accordance with applicable participant privacy regulations
* Diagnosis of MS, including Clinically Isolated Syndrome
* Ability to understand the audio and visual instructions for the test modules
* Visual function, based on the investigator's clinical judgement that does not preclude an ability to interact with the Multiple Sclerosis Performance Test (MSPT).

Exclusion Criteria

* Unable or unwilling to provide informed consent
* Participants younger than 18 years of age, unless their parent or legal guardian provides the required signed and dated informed consent and authorization to use confidential health information and the participant provides assent in accordance with national and local subject privacy regulations
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Biogen

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Director

Role: STUDY_DIRECTOR

Biogen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Berkeley, California, United States

Site Status

Research Site

Los Angeles, California, United States

Site Status

Research Site

Aurora, Colorado, United States

Site Status

Research Site

Washington D.C., District of Columbia, United States

Site Status

Research Site

Atlanta, Georgia, United States

Site Status

Research Site

Atlanta, Georgia, United States

Site Status

Research Site

Chicago, Illinois, United States

Site Status

Research Site

Boston, Massachusetts, United States

Site Status

Research Site

Farmington Hills, Michigan, United States

Site Status

Research Site

Owosso, Michigan, United States

Site Status

Research Site

St Louis, Missouri, United States

Site Status

Research Site

Teaneck, New Jersey, United States

Site Status

Research Site

Buffalo, New York, United States

Site Status

Research Site

Durham, North Carolina, United States

Site Status

Research Site

Oklahoma City, Oklahoma, United States

Site Status

Research Site

Portland, Oregon, United States

Site Status

Research Site

Philadelphia, Pennsylvania, United States

Site Status

Research Site

Pittsburgh, Pennsylvania, United States

Site Status

Research Site

Dallas, Texas, United States

Site Status

Research Site

Salt Lake City, Utah, United States

Site Status

Research Site

Seattle, Washington, United States

Site Status

Research Site

Spokane, Washington, United States

Site Status

Research Site

Prague, , Czechia

Site Status

Research Site

Strasbourg, , France

Site Status

Research Site

Bari, , Italy

Site Status

Research Site

Catania, , Italy

Site Status

Research Site

Milan, , Italy

Site Status

Research Site

Orbassano, , Italy

Site Status

Research Site

Roma, , Italy

Site Status

Research Site

Basel, , Switzerland

Site Status

Research Site

Bern, , Switzerland

Site Status

Research Site

Camberley, , United Kingdom

Site Status

Research Site

Oxford, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Czechia France Italy Switzerland United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

US-MSG-18-11424

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study for Patients With Multiple Sclerosis
NCT00870155 TERMINATED PHASE2/PHASE3
ATX-MS-1467 in Multiple Sclerosis
NCT01973491 COMPLETED PHASE2
Efficacy and Safety of BG00012 in MS
NCT00168701 COMPLETED PHASE2
MitoQ for Fatigue in Multiple Sclerosis
NCT03166800 TERMINATED PHASE1/PHASE2
Serum Neurofilament Light in Multiple Sclerosis
NCT06282081 ACTIVE_NOT_RECRUITING